Literature DB >> 18211930

Recurrence characteristics in European patients with ocular toxoplasmosis.

J G Garweg1, J N Scherrer, M Halberstadt.   

Abstract

BACKGROUND: The risk of function loss after each episode of ocular toxoplasmosis (OT) supports efforts to improve our understanding of the disease. PATIENTS AND METHODS: 139 patients with OT were contacted retrospectively and requested to complete a questionnaire addressing course and activity of their disease. This information was compared with that retrieved from their medical records. Sixty-three patients completed the questionnaire and were included in the study. They were allocated according to their median age to one of two groups (group 1: <20.9 years; group 2: >or=20.9 years).
RESULTS: The mean reported age at the time of first ocular manifestation was 23.9 (median 20.9, range 0 to 70.5; SD 12.9) years. The clinical diagnosis was made 3.5 years later (p = 0.0008). The follow-up time was 6.5 (median 5.0; range 0.5 to 49.9; SD 7.6) years. The recurrence rate was higher in patients below 20.9 years (66%; n = 35) than in older patients (39%; n = 28; chi(2) test, p<0.05). Patients reporting only one episode were older at first manifestation (29.6 (median 25.6; range 10.6 to 70.5; SD 14.3) years; n = 29) than those reporting two episodes (17.9 (median 19.5; range 5.9 to 33.9; SD 7.8) years; n = 15 (p<0.05)). The proportion of patients who developed a recurrence was 54-63% after each episode without a tendency to enlarge, and the interval between successive episodes remained stable between 1.0 and 1.7 years for the first three recurrences.
CONCLUSION: Younger OT patients carry a higher risk of developing a recurrence than older ones. After each episode, two-thirds of all OT patients will develop another one.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18211930     DOI: 10.1136/bjo.2007.123661

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Toxoplasmosis: new challenges for an old disease.

Authors:  B Bodaghi; V Touitou; C Fardeau; L Paris; P LeHoang
Journal:  Eye (Lond)       Date:  2012-01-06       Impact factor: 3.775

Review 2.  Toxoplasmosis in Germany.

Authors:  Uwe Pleyer; Uwe Gross; Dirk Schlüter; Henrik Wilking; Frank Seeber
Journal:  Dtsch Arztebl Int       Date:  2019-06-21       Impact factor: 5.594

3.  Clinical pattern of ocular toxoplasmosis treated in a referral centre in Serbia.

Authors:  D Kovačević-Pavićević; A Radosavljević; A Ilić; I Kovačević; O Djurković-Djaković
Journal:  Eye (Lond)       Date:  2012-02-24       Impact factor: 3.775

4.  Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?

Authors:  Sibylle Winterhalter; Katja Severing; Johannes Stammen; Anna Karina Maier; Erhard Godehardt; Antonia Maria Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

Review 5.  Ocular toxoplasmosis II: clinical features, pathology and management.

Authors:  Nicholas J Butler; João M Furtado; Kevin L Winthrop; Justine R Smith
Journal:  Clin Exp Ophthalmol       Date:  2012-09-17       Impact factor: 4.207

6.  Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran.

Authors:  Seyedeh Maryam Hosseini; Elham Moghaddas; Karim Sharifi; Malihe Dadgar Moghaddam; Seyed Aliakbar Shamsian
Journal:  Int Ophthalmol       Date:  2018-01-15       Impact factor: 2.031

7.  Immune Mediator Profile in Aqueous Humor Differs in Patients with Primary Acquired Ocular Toxoplasmosis and Recurrent Acute Ocular Toxoplasmosis.

Authors:  Claudia Thieme; Stephan Schlickeiser; Sylvia Metzner; Claudia Dames; Uwe Pleyer
Journal:  Mediators Inflamm       Date:  2019-02-17       Impact factor: 4.711

8.  Toxoplasmic retinochoroiditis: The influence of age, number of retinochoroidal lesions and genetic polymorphism for IFN-γ +874 T/A as risk factors for recurrence in a survival analysis.

Authors:  Ana Luisa Quintella do Couto Aleixo; Raquel Vasconcelos C de Oliveira; Maíra Cavalcanti Albuquerque; Ana Luiza Biancardi; André Luiz Land Curi; Eliezer Israel Benchimol; Maria Regina Reis Amendoeira
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

9.  Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study.

Authors:  Ana Luisa Quintella do Couto Aleixo; André Luiz Land Curi; Eliezer Israel Benchimol; Maria Regina Reis Amendoeira
Journal:  PLoS Negl Trop Dis       Date:  2016-05-02

10.  The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence.

Authors:  Piotr K Borkowski; Joanna Brydak-Godowska; Wojciech Basiak; Karolina Świtaj; Hanna Żarnowska-Prymek; Maria Olszyńska-Krowicka; Piotr Kajfasz; Daniel Rabczenko
Journal:  PLoS Negl Trop Dis       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.